Preliminary observation of PAUL glaucoma implant in glaucoma treatment
10.3980/j.issn.1672-5123.2024.7.31
- VernacularTitle:保罗青光眼植入物治疗青光眼的初步观察
- Author:
Tian HU
1
;
Zhiqi CHEN
1
;
Hong ZHANG
1
Author Information
1. Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China; Jiangxi Provincial People's Hospital;the First Affiliated Hospital of Nanchang Medical College, Nanchang 330000, Jiangxi Province, China
- Publication Type:Journal Article
- Keywords:
PAUL glaucoma implant;
glaucoma;
intraocular pressure;
surgical outcomes;
safety
- From:
International Eye Science
2024;24(7):1168-1172
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To preliminarily assess the efficacy and safety of PAUL glaucoma implant in glaucoma management.METHODS: Clinical data of 10 glaucoma patients(10 eyes)who treated with Paul's glaucoma implant from March 2022 to January 2023 were retrospectively analyzed. A follow-up of 12 mo was performed to observe changes in visual acuity, intraocular pressure, and number of anti-glaucoma medications before and after surgery.RESULTS: Included patients had no significant change in visual acuity from preoperative to last follow-up; preoperative intraocular pressure was 19-60(median 28)mmHg, and it was 10-18(median 14)mmHg at last follow-up. All patients required two to four antiglaucoma medications preoperatively, and only 1 case needed medications at final follow-up. Four patients had a significant decrease in corneal endothelial cell density compared with the preoperative period, and no corneal-related complications occurred. At final follow-up, all 10 patients met surgical success criteria.CONCLUSION: PAUL glaucoma implant has significant IOP lowering efficacy and that corneal endothelial cell damage may be a pitfall of its presence.
